An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy

NCT ID: NCT01665911

Last Updated: 2015-02-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect. Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies. While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs. This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT). The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area. After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture. During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period. Fluoride free toothpaste will be used two to three days before and continuously during each treatment period. After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test. Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable. Each subject (n = 28) will serve as his or her own control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk

Group Type OTHER

1.5 mg Sodium Fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1.5 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design

Non-fluoridated milk, 200 ml

Intervention Type OTHER

Each subject will use this product during one of the five treatment periods in the crossover study design.

Arm 2

non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk

Group Type OTHER

1.5 mg Sodium Fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1.5 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design

Non-fluoridated milk, 200 ml

Intervention Type OTHER

Each subject will use this product during one of the five treatment periods in the crossover study design.

Arm 3

non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk

Group Type OTHER

1.5 mg Sodium Fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1.5 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design

Non-fluoridated milk, 200 ml

Intervention Type OTHER

Each subject will use this product during one of the five treatment periods in the crossover study design.

Arm 4

non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk

Group Type OTHER

1.5 mg Sodium Fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1.5 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design

Non-fluoridated milk, 200 ml

Intervention Type OTHER

Each subject will use this product during one of the five treatment periods in the crossover study design.

Arm 5

non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk

Group Type ACTIVE_COMPARATOR

1.5 mg Sodium Fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1.5 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 100 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

3 mg sodium fluoride in 200 ml milk

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design

Non-fluoridated milk, 200 ml

Intervention Type OTHER

Each subject will use this product during one of the five treatment periods in the crossover study design.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1.5 mg Sodium Fluoride in 100 ml milk

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

1.5 mg sodium fluoride in 200 ml milk

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

3 mg sodium fluoride in 100 ml milk

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

3 mg sodium fluoride in 200 ml milk

Each subject will use this product during one of the five treatment periods in the crossover study design

Intervention Type DRUG

Non-fluoridated milk, 200 ml

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00) Kroger Nonfat Dry Milk reconstituted with fluoride-free milk sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00) Kroger Nonfat Dry Milk reconstituted with fluoride-free milk sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00) Kroger Nonfat Dry Milk reconstituted with fluoride-free milk sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00) Kroger Nonfat Dry Milk reconstituted with fluoride-free milk Kroger Nonfat Dry Milk

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
* be between 18 and 80 years old and in general good health;
* willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
* wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
* be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
* be in good dental health with no active caries or periodontal disease;
* agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
* have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
* Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening

Exclusion Criteria

be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.

* have any medical condition that could be expected to interfere with the subject's safety during the study period;
* demonstrate an inability to comply with study procedures;
* have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning\* or previous use of the weight loss medications Fen Phen® or Redux®. (\*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
* be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
* be lactose intolerant or have known allergy or intolerance to milk or milk products
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Borrow Foundation

UNKNOWN

Sponsor Role collaborator

Frank Lippert

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Frank Lippert

Assistant Research Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank Lippert, PhD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Domenick Zero, DDS, MS

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oral Health Research Institute, Indiana University School of Dentistry

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Lippert F, Martinez-Mier EA, Zero DT. An in situ caries study on the interplay between fluoride dose and concentration in milk. J Dent. 2014 Jul;42(7):883-90. doi: 10.1016/j.jdent.2014.01.010. Epub 2014 Feb 7.

Reference Type RESULT
PMID: 24513113 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-I-086

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.